The Triple-Agonist Frontier: Understanding Retatrutide and the Risks of Unregulated Weight-Loss Trends
Raul Delapena Setiawan
The landscape of obesity medicine is undergoing a seismic shift. In recent years, the arrival of GLP-1 receptor agonists—such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound)—has revolutionized clinical approaches to…
